Latentautoimmune diabetes of adulthood (LADA) is a new term for patients whose diabetes more closely resembles type 1 diabetes, but don't quite have all the symptoms. Often misdiagnosed as type 2 diabetes, LADA – also sometimes called type 1.5 diabetes – is believed to be a slowly progress...
SGLT2 inhibitors, such as cangliflozin (Invokana), dapagliflozin (Farxiga), or empagliflozin (Jardiance) Insulin Other Prescriptions to treat coexisting health conditions such as high blood pressure, high cholesterol, or low-dose aspirin to reduce the risk of a heart attack.Drugs...
SGLT2 Inhibitor Lowers glucose, taken for longevityDr. Peter Attia’s daily supplements, sleep aids, and prescription medication For a detailed breakdown of what else this article covers, see the table of contents below: Table of Contents Daily Supplements Omega-3 Fish Oil While Peter’s supple...
Costs and where to find them: identifying unit costs for health economic evaluations of diabetes in France, Germany and Italy Article Open access 06 October 2020 Introduction Diabetes imposes substantial economic and health burdens on individuals and society. According to International Diabetes Federation...
Key words: SGLT2i, Diabetic cardiomyopathy, Cellular senescence, ANGPTL4, FOXO1 [more] Organism: Mouse Tissue: Heart Pathological State: Diabetes 29 Expression of Neurotrophins and Its Receptors During Fetal Development in the Human Cochlea C Steinacher, Sy Nishio, Si Usami, J Dudas, D Rieder...
Sodium-glucose cotransporter 2, or SGLT2 inhibitors, originally developed as glucose-lowering drugs, have also been found to help people with severe heart failure and chronic kidney disease, whether they had diabetes or not. New research from three separate analyses, astudyon people with mild hear...
Episode 3: SGLT2 Inhibitors: A Future in Cardiorenal Metabolic SyndromeJoin Drs Nihar Desai and Jay Udell as they discuss the role of SGLT2 inhibitors in the treatment of cardiorenal metabolic syndrome. Medscape, July 18, 2024 Are US Electrophysiologists Too Easily Impressed?Electrophysiologists ado...
Episode 3: SGLT2 Inhibitors: A Future in Cardiorenal Metabolic Syndrome Join Drs Nihar Desai and Jay Udell as they discuss the role of SGLT2 inhibitors in the treatment of cardiorenal metabolic syndrome. Medscape, July 18, 2024 Are US Electrophysiologists Too Easily Impressed? Electrophysiologists...
Dec 01 2023 This Week in CardiologyMore from AHA including SGLT2 inhibitors, blood transfusion after MI; cracks in the armor of Factor XI inhibitors; and renal denervation are the topics John Mandrola, MD, covers in this week’s podcast. ...
trials for all novel antidiabetic agents [i.e., dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors), glucagon-like peptide-1 receptor agonists (GLP-1 RAs), and sodium-glucose cotransporter-2 inhibitors (SGLT2is)] with the aim to assess the CV safety of these drugs beyond glycemic control....